Accueil>>Signaling Pathways>> PROTAC>>HaloPROTAC 2

HaloPROTAC 2 (Synonyms: HaloPROTAC 2)

Catalog No.GC32831

HaloPROTAC 2 (HaloPROTAC 2) est un conjugué de ligands pour E3 et un lieur de 21 atomes de longueur. Le connecteur du lieur est le groupe halogène. HaloPROTAC 2 intègre le ligand VHL basé sur VH032 et le lieur PEG À 5 unités. HaloPROTAC 2 est capable d'induire la dégradation de GFP-HaloTag7 dans les tests cellulaires.

Products are for research use only. Not for human use. We do not sell to patients.

HaloPROTAC 2 Chemical Structure

Cas No.: 1799506-06-1

Taille Prix Stock Qté
10mM (in 1mL DMSO)
496,00 $US
En stock
5mg
346,00 $US
En stock
10mg
576,00 $US
En stock
25mg
1 152,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

HaloPROTAC 2, a chloroalkane-containing PROTAC, induces degradation of HaloTag fusion proteins.

HaloPROTAC 1 and HaloPROTAC2, containing different linker lengths, are synthesized. Their ability to degrade GFP-HaloTag7, (stably expressed in HEK 293 cells) is tested tby flow cytometry, measuring changes in mean fluorescence intensity. While 24 hour treatment with HaloPROTAC 1 leads to less than 20% degradation, the longer HaloPROTAC2 leads to nearly 70% degradation of GFP-Halotag7 at 2.5 μM[1].

[1]. Buckley DL, et al. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. ACS Chem Biol. 2015 Aug 21;10(8):1831-7.

Avis

Review for HaloPROTAC 2

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for HaloPROTAC 2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.